Get the Stockscreener App
2.86
4.98%
-0.15
After Hours:
2.80
-0.06
-2.10%
Senti Biosciences Inc stock is traded at $2.86, with a volume of 29,040.
It is down -4.98% in the last 24 hours and down -34.85% over the past month.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
See More
Previous Close:
$3.01
Open:
$3.05
24h Volume:
29,040
Relative Volume:
0.01
Market Cap:
$14.01M
Revenue:
$1.79M
Net Income/Loss:
$-70.90M
P/E Ratio:
-0.184
EPS:
-15.54
Net Cash Flow:
$-34.95M
1W Performance:
-25.71%
1M Performance:
-34.85%
6M Performance:
+8.75%
1Y Performance:
-33.64%
1-Day Range:
$2.75
$3.15
1-Week Range:
$2.63
$3.90
52-Week Range:
$1.5201
$16.94
Senti Biosciences Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Inc
Sector
Industry
Phone
(650) 382-3281
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
2.86 | 14.01M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Stock (SNTI) Latest News
Comparing Senti Biosciences (NASDAQ:SNTI) and Windtree Therapeutics (NASDAQ:WINT) - Defense World
NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.
Senti Biosciences Appoints New CFO Jay Cross - TipRanks
Senti Bio appoints Jay Cross as CFO - TipRanks
Senti Biosciences expands leadership with new CFO and SVP By Investing.com - Investing.com Canada
Senti Biosciences expands leadership with new CFO and SVP - Investing.com India
Senti Bio Strengthens Leadership Team with Strategic Hires - The Manila Times
Can Senti Bio's New Executives Accelerate Its Novel Cell Therapy Programs? - StockTitan
Senti Biosciences (SNTI) Stock Price, News & Analysis - MarketBeat
Senti Biosciences (NASDAQ:SNTI) versus IN8bio (NASDAQ:INAB) Critical Contrast - Defense World
Senti Biosciences CEO Timothy Lu sells shares worth $18,338 - MSN
Senti Biosciences executive sells $6,074 in stock - MSN
Senti Biosciences Renews Consulting Agreement with Yvonne Li - TipRanks
Senti Biosciences CFO transitions to consultant role - Investing.com
Senti Biosciences CFO transitions to consultant role By Investing.com - Investing.com UK
US Penny Stocks To Watch In January 2025 - Yahoo Finance
Critical Comparison: Senti Biosciences (NASDAQ:SNTI) and Ginkgo Bioworks (NYSE:DNA) - Defense World
Senti Bio Announces Additional $11.5 Million of Financing - The Manila Times
Senti Biosciences secures additional $10 million investment By Investing.com - Investing.com
Senti Bio announces additional $11.5M in financing - TipRanks
Senti Bio Secures $11.5M Boost: Extends Cash Runway to 2026 with New Funding Round - StockTitan
How Is The Market Feeling About Senti Biosciences? - Benzinga
Sangamo Therapeutics (NASDAQ:SGMO) & Senti Biosciences (NASDAQ:SNTI) Head-To-Head Comparison - Defense World
Comparing VectivBio (NASDAQ:VECT) and Senti Biosciences (NASDAQ:SNTI) - Defense World
Senti Biosciences (NASDAQ:SNTI) & BioNTech (NASDAQ:BNTX) Head to Head Review - Defense World
Senti Bio Launches Groundbreaking CAR-NK Cell Therapy Trial for Liver Cancer in China - StockTitan
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics - Yahoo Finance
Cathie Wood's ARK buys Tempus AI stock, sheds Senti Biosciences - Investing.com India
Cathie Wood's ARK buys Tempus AI stock, sheds Senti Biosciences By Investing.com - Investing.com Nigeria
Chardan Capital Has Negative Outlook of SNTI FY2024 Earnings - Defense World
Cathie Wood's ARK buys ABSI stock, sells BFLY and SNTI - Investing.com India
Senti Bio price target raised to $12 from $10 at Chardan - Yahoo Finance
Senti Biosciences Skyrockets 400% On Oversubscribed PIPE Deal, Promising Cancer Trial Data: Retail Overjoyed - MSN
Chardan lifts Senti Biosciences stock target on positive trial data By Investing.com - Investing.com Nigeria
Chardan lifts Senti Biosciences stock target on positive trial data - Investing.com
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study - MSN
Senti Biosciences Announces New Employment Inducement Grants - The Manila Times
Senti Biosciences Approves New Employee Stock Options in Latest Inducement Grants - StockTitan
Stock market news: Sharps Technology -34.40%, Senti Biosciences -28.60% among biggest losers during mid day trading - Business Upturn
Stock market news: Exicure -34.53%, Senti Biosciences -23.70% among biggest losers in early trading - Business Upturn
Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202 - Yahoo Finance
Senti Biosciences reports early success in AML trial - The Pharma Letter
Senti Bio appoints new board member and audit chair By Investing.com - Investing.com Canada
Senti Biosciences, Inc. announced that it expects to receive $37.60425 million in funding from Celadon Partners, New Enterprise Associates, Inc., Leaps by Bayer, Nantahala Capital Management, LLC and other investors - Marketscreener.com
Senti Biosciences, Inc. (SNTI) could keep surging and here’s why - BP Journal
Senti Biosciences Advances with Key Financial and Strategic Moves - TipRanks
Senti Biosciences Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Senti Biosciences Inc Stock (SNTI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lu Timothy K | CEO |
Feb 06 '25 |
Sale |
4.36 |
545 |
2,376 |
82,082 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 04 '25 |
Sale |
4.07 |
1,297 |
5,279 |
8,803 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 06 '25 |
Sale |
4.37 |
182 |
795 |
8,621 |
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):